GILD · 10-Q · 2026Q3 · Full report

Revenue Performance and Mix

GILEAD SCIENCES, INC. · 2026-10-30 · Importance 43 · Surprise 32 · No source text

Total revenues increased 7% to $8.3 billion for the three months and $23.1 billion for the nine months ended September 30, 2026, compared with the same periods in 2025. Nine-month HIV product sales rose 14% to $17.0 billion, driven by Biktarvy sales growth of 8%, Descovy growth of 45%, and higher Yeztugo demand. Liver Disease sales increased 8% to $2.6 billion for the nine-month period, while Trodelvy sales rose 35% to $1.4 billion; Veklury sales fell 64% to $253 million and Cell Therapy sales fell 15% to $1.2 billion. Royalty, contract and other revenues decreased to $201 million for the nine months, primarily because the prior-year period included $400 million of previously constrained revenue from an intellectual property sale.

Key facts

• Gilead’s total revenues increased 7% to $8.3 billion for the three months and $23.1 billion for the nine months ended September 30, 2026, primarily from higher HIV, Trodelvy and Livdelzi sales, partly offset by lower Veklury and Cell Therapy sales and lower royalty, contract and other revenues. source
• Gilead’s royalty, contract and other revenues were $11 million and $201 million for the three and nine months ended September 30, 2026, respectively; the decrease primarily reflected $400 million recognized in Q3 2025 from a prior intellectual-property sale, partly offset for the nine-month period by $156 million recognized in Q2 2026. source
• Nine-month 2026 total revenues were also affected by lower chronic HCV product sales. source
• Foreign exchange, net of hedges, favorably affected Gilead’s total product sales by $127 million for the nine months ended September 30, 2026. source
• Foreign exchange, net of hedges, unfavorably affected Gilead’s Q3 2026 total product sales by $8 million. source

Impact estimates